Inno Peptides
Inno Peptides shows a recent, purity-led record across GHK-Cu, Retatrutide, and Tirzepatide, with repeated identity passes and 99.6–99.9% purity. The weaker shape is fill and documentation dispersion: Retatrutide and Tirzepatide include sizable low fills and missing batch IDs, while GHK-Cu's strong score rests on a shorter history.
Corporate archives tie Inno Peptides to a Wuhan chemical-export network, while domain records show a renewed but parked storefront and continuing DM sales. The report separates it from the similarly named InnoPeptide and traces counterfeit-HGH, impersonation, and payment-recourse signals.
Unlock original COAs
View and download original lab PDFs for Finnrick tests, including Inno Peptides rows.
Cancel anytime
| Date | Result | Test | Lab | Purity | Dosage | Label | COA |
|---|---|---|---|---|---|---|---|
| 4 Aug 2026 | Pass | Retatrutide Inno Peptides | lab name | View COA | |||
| 4 Aug 2026 | Pass | Retatrutide Inno Peptides | lab name | View COA | |||
| 3 Aug 2026 | Pass | Retatrutide Inno Peptides | lab name | View COA | |||
| 3 Aug 2026 | Fail | Tirzepatide Inno Peptides | lab name | View COA | |||
| 3 Aug 2026 | Pass | GHK-Cu Inno Peptides | lab name | View COA | |||
| 17 Jul 2026 | Pass | Retatrutide Inno Peptides | lab name | View COA | |||
| 15 Jul 2026 | Pass | Retatrutide Inno Peptides | lab name | View COA | |||
| 13 Jul 2026 | Pass | Tirzepatide Inno Peptides | lab name | View COA | |||
| 26 Jun 2026 | Pass | Retatrutide Inno Peptides | lab name | View COA | |||
| 26 Jun 2026 | Incomplete | Retatrutide Inno Peptides | lab name | View COA | |||
About Inno Peptides test results from Finnrick
Inno Peptides is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 3 peptides and 28 tests, including ratings, observed price signals, recent test dates, and correction history where available.
Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.
The most visible Inno Peptides peptides in this dataset are Retatrutide (15 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.
Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 28 recent tests.